Costs of adverse events associated with erlotinib or afatinib in first-line treatment of advanced EGFR-positive non-small cell lung cancer

OBJECTIVES: Epidermal growth factor receptor–tyrosine kinase inhibitors (EGFR-TKIs) are an established treatment for advanced non-small cell lung cancer (NSCLC) with EGFR mutation. According to published meta-analyses, no significant efficacy differences have been demonstrated between erlotinib and...

Descripción completa

Detalles Bibliográficos
Autores principales: Isla, Dolores, De Castro, Javier, Juan, Oscar, Grau, Santiago, Orofino, Javier, Gordo, Rocío, Rubio-Terrés, Carlos, Rubio-Rodríguez, Darío
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5221482/
https://www.ncbi.nlm.nih.gov/pubmed/28115857
http://dx.doi.org/10.2147/CEOR.S121093

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5221482/
https://www.ncbi.nlm.nih.gov/pubmed/28115857
http://dx.doi.org/10.2147/CEOR.S121093

Ejemplares similares